{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:52:11Z","timestamp":1792738331287,"version":"4.5.0"},"reference-count":284,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41585-025-01104-9","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T16:45:51Z","timestamp":1762793151000},"page":"358-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["20 years of taxane therapy in prostate cancer \u2014 the past, present and future"],"prefix":"10.1038","volume":"23","author":[{"given":"Marc","family":"Carceles-Cordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Rodriguez-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Domingo-Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"1104_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1104_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/jnci\/83.4.288","volume":"83","author":"I Ringel","year":"1991","unstructured":"Ringel, I. & Horwitz, S. B. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl Cancer Inst. 83, 288\u2013291 (1991).","journal-title":"J. Natl Cancer Inst."},{"key":"1104_CR3","first-page":"534","volume":"18","author":"J Guevara","year":"1975","unstructured":"Guevara, J., Sukerman, M. & Velasco, M. A randomized double-blind study of timolol in patients with essential hypertension. Curr. Ther. Res. Clin. Exp. 18, 534\u2013538 (1975).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"1104_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502\u20131512 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513\u20131520 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR6","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock, I. F. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756\u20131764 (1996).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR7","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","volume":"296","author":"IM Thompson","year":"2006","unstructured":"Thompson, I. M. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer a randomized clinical trial. JAMA 296, 2329\u20132335 (2006).","journal-title":"JAMA"},{"key":"1104_CR8","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","volume":"17","author":"PW Kantoff","year":"1999","unstructured":"Kantoff, P. W. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 17, 2506\u20132513 (1999).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2001.19.9.2509","volume":"19","author":"DM Savarese","year":"2001","unstructured":"Savarese, D. M. et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and leukemia group B. J. Clin. Oncol. 19, 2509\u20132516 (2001).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR10","first-page":"4573","volume":"53","author":"B Dahll\u00f6f","year":"1993","unstructured":"Dahll\u00f6f, B., Billstr\u00f6m, A., Cabral, F. & Hartley-Asp, B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53, 4573\u20134581 (1993).","journal-title":"Cancer Res."},{"key":"1104_CR11","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/jnci\/86.9.688","volume":"86","author":"LA Speicher","year":"1994","unstructured":"Speicher, L. A. et al. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J. Natl Cancer Inst. 86, 688\u2013694 (1994).","journal-title":"J. Natl Cancer Inst."},{"key":"1104_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0022-5347(17)45620-5","volume":"135","author":"HJ de Voogt","year":"1986","unstructured":"de Voogt, H. J., Smith, P. H., Pavone-Macaluso, M., de Pauw, M. & Suciu, S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European organization for research on treatment of cancer trials 30761 and 30762. J. Urol. 135, 303\u2013307 (1986).","journal-title":"J. Urol."},{"key":"1104_CR13","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad, F. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94, 1458\u20131468 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"1104_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamaoncol.2015.5570","volume":"2","author":"ND James","year":"2016","unstructured":"James, N. D. et al. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the TRAPEZE randomized clinical trial. JAMA Oncol. 2, 493\u2013499 (2016).","journal-title":"JAMA Oncol."},{"key":"1104_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"G Gravis","year":"2016","unstructured":"Gravis, G. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur. Urol. 70, 256\u2013262 (2016).","journal-title":"Eur. Urol."},{"key":"1104_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36, 1080\u20131087 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR18","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353\u20132366 (2018).","journal-title":"Lancet"},{"key":"1104_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design. Lancet 399, 1695\u20131707 (2022).","journal-title":"Lancet"},{"key":"1104_CR20","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. 386, 1132\u20131142 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147\u20131154 (2010).","journal-title":"Lancet"},{"key":"1104_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrd3254","volume":"9","author":"MD Galsky","year":"2010","unstructured":"Galsky, M. D., Dritselis, A., Kirkpatrick, P. & Oh, W. K. Cabazitaxel. Nat. Rev. Drug. Discov. 9, 677\u2013678 (2010).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1104_CR23","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger, M. et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J. Clin. Oncol. 35, 3198\u20133206 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR24","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard, S. et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III Trial-FIRSTANA. J. Clin. Oncol. 35, 3189\u20133197 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR25","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/cam4.344","volume":"3","author":"G Barnes","year":"2014","unstructured":"Barnes, G., Pathak, A. & Schwartzberg, L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med. 3, 1477\u20131484 (2014).","journal-title":"Cancer Med."},{"key":"1104_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CAD.0b013e32835a56bc","volume":"24","author":"G Di Lorenzo","year":"2013","unstructured":"Di Lorenzo, G. et al. Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer. Drugs 24, 84\u201389 (2013).","journal-title":"Anticancer. Drugs"},{"key":"1104_CR27","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit, R. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381, 2506\u20132518 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2021.10.016","volume":"81","author":"G Baciarello","year":"2022","unstructured":"Baciarello, G. et al. Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: the CABADOC trial. Eur. Urol. 81, 234\u2013240 (2022).","journal-title":"Eur. Urol."},{"key":"1104_CR29","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jamaoncol.2023.4255","volume":"9","author":"S Oudard","year":"2023","unstructured":"Oudard, S. et al. Biweekly vs triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer: the CABASTY phase 3 randomized clinical trial. JAMA Oncol. 9, 1629\u20131638 (2023).","journal-title":"JAMA Oncol."},{"key":"1104_CR30","first-page":"953","volume":"32","author":"P Hervonen","year":"2012","unstructured":"Hervonen, P. et al. Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer. Anticancer. Res. 32, 953\u2013956 (2012).","journal-title":"Anticancer. Res."},{"key":"1104_CR31","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly, W. K. et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30, 1534\u20131540 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/pcan.2013.2","volume":"16","author":"K Miller","year":"2013","unstructured":"Miller, K. et al. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 16, 187\u2013192 (2013).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1104_CR33","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","volume":"14","author":"IF Tannock","year":"2013","unstructured":"Tannock, I. F. et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 14, 760\u2013768 (2013).","journal-title":"Lancet Oncol."},{"key":"1104_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1470-2045(15)70025-2","volume":"16","author":"DP Petrylak","year":"2015","unstructured":"Petrylak, D. P. et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 16, 417\u2013425 (2015).","journal-title":"Lancet Oncol."},{"key":"1104_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/312237a0","volume":"312","author":"T Mitchison","year":"1984","unstructured":"Mitchison, T. & Kirschner, M. Dynamic instability of microtubule growth. Nature 312, 237\u2013242 (1984).","journal-title":"Nature"},{"key":"1104_CR36","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1073\/pnas.82.10.3267","volume":"82","author":"M Caplow","year":"1985","unstructured":"Caplow, M. & Reid, R. Directed elongation model for microtubule GTP hydrolysis. Proc. Natl Acad. Sci. USA 82, 3267\u20133271 (1985).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR37","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1021\/bi00535a017","volume":"21","author":"MF Carlier","year":"1982","unstructured":"Carlier, M. F. & Pantaloni, D. Assembly of microtubule protein: role of guanosine di- and triphosphate nucleotides. Biochemistry 21, 1215\u20131224 (1982).","journal-title":"Biochemistry"},{"key":"1104_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nsb0698-451","volume":"5","author":"E Nogales","year":"1998","unstructured":"Nogales, E., Downing, K. H., Amos, L. A. & L\u00f6we, J. Tubulin and FtsZ form a distinct family of GTPases. Nat. Struct. Biol. 5, 451\u2013458 (1998).","journal-title":"Nat. Struct. Biol."},{"key":"1104_CR39","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1021\/bi00510a030","volume":"20","author":"MF Carlier","year":"1981","unstructured":"Carlier, M. F. & Pantaloni, D. Kinetic analysis of guanosine 5\u2019-triphosphate hydrolysis associated with tubulin polymerization. Biochemistry 20, 1918\u20131924 (1981).","journal-title":"Biochemistry"},{"key":"1104_CR40","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0960-9822(00)00243-8","volume":"4","author":"DN Drechsel","year":"1994","unstructured":"Drechsel, D. N. & Kirschner, M. W. The minimum GTP cap required to stabilize microtubules. Curr. Biol. CB 4, 1053\u20131061 (1994).","journal-title":"Curr. Biol. CB"},{"key":"1104_CR41","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1083\/jcb.201612104","volume":"217","author":"FJ McNally","year":"2018","unstructured":"McNally, F. J. & Roll-Mecak, A. Microtubule-severing enzymes: from cellular functions to molecular mechanism. J. Cell Biol. 217, 4057\u20134069 (2018).","journal-title":"J. Cell Biol."},{"key":"1104_CR42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0092-8674(93)90377-3","volume":"75","author":"FJ McNally","year":"1993","unstructured":"McNally, F. J. & Vale, R. D. Identification of katanin, an ATPase that severs and disassembles stable microtubules. Cell 75, 419\u2013429 (1993).","journal-title":"Cell"},{"key":"1104_CR43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/330181a0","volume":"330","author":"BM Paschal","year":"1987","unstructured":"Paschal, B. M. & Vallee, R. B. Retrograde transport by the microtubule-associated protein MAP 1C. Nature 330, 181\u2013183 (1987).","journal-title":"Nature"},{"key":"1104_CR44","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrm2774","volume":"10","author":"N Hirokawa","year":"2009","unstructured":"Hirokawa, N., Noda, Y., Tanaka, Y. & Niwa, S. Kinesin superfamily motor proteins and intracellular transport. Nat. Rev. Mol. Cell Biol. 10, 682\u2013696 (2009).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1104_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0092-8674(01)00364-6","volume":"105","author":"SC Schuyler","year":"2001","unstructured":"Schuyler, S. C. & Pellman, D. Microtubule \u2018plus-end-tracking proteins\u2019: the end is just the beginning. Cell 105, 421\u2013424 (2001).","journal-title":"Cell"},{"key":"1104_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrm2369","volume":"9","author":"A Akhmanova","year":"2008","unstructured":"Akhmanova, A. & Steinmetz, M. O. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Nat. Rev. Mol. Cell Biol. 9, 309\u2013322 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1104_CR47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrm4084","volume":"16","author":"A Akhmanova","year":"2015","unstructured":"Akhmanova, A. & Steinmetz, M. O. Control of microtubule organization and dynamics: two ends in the limelight. Nat. Rev. Mol. Cell Biol. 16, 711\u2013726 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1104_CR48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1073\/pnas.72.1.177","volume":"72","author":"RD Sloboda","year":"1975","unstructured":"Sloboda, R. D., Rudolph, S. A., Rosenbaum, J. L. & Greengard, P. Cyclic AMP-dependent endogenous phosphorylation of a microtubule-associated protein. Proc. Natl Acad. Sci. USA 72, 177\u2013181 (1975).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR49","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","volume":"72","author":"MD Weingarten","year":"1975","unstructured":"Weingarten, M. D., Lockwood, A. H., Hwo, S. Y. & Kirschner, M. W. A protein factor essential for microtubule assembly. Proc. Natl Acad. Sci. USA 72, 1858\u20131862 (1975).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR50","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0022-2836(77)90213-3","volume":"116","author":"DW Cleveland","year":"1977","unstructured":"Cleveland, D. W., Hwo, S. Y. & Kirschner, M. W. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 116, 207\u2013225 (1977).","journal-title":"J. Mol. Biol."},{"key":"1104_CR51","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1073\/pnas.051309398","volume":"98","author":"JP Snyder","year":"2001","unstructured":"Snyder, J. P., Nettles, J. H., Cornett, B., Downing, K. H. & Nogales, E. The binding conformation of taxol in beta-tubulin: a model based on electron crystallographic density. Proc. Natl Acad. Sci. USA 98, 5312\u20135316 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253\u2013265 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"1104_CR53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.tcb.2014.08.006","volume":"25","author":"C Sacristan","year":"2015","unstructured":"Sacristan, C. & Kops, G. J. P. L. Joined at the hip: kinetochores, microtubules, and spindle assembly checkpoint signaling. Trends Cell Biol. 25, 21\u201328 (2015).","journal-title":"Trends Cell Biol."},{"key":"1104_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2005.06.011","volume":"8","author":"BAA Weaver","year":"2005","unstructured":"Weaver, B. A. A. & Cleveland, D. W. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8, 7\u201312 (2005).","journal-title":"Cancer Cell"},{"key":"1104_CR55","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4161\/cc.6.1.3682","volume":"6","author":"MV Blagosklonny","year":"2007","unstructured":"Blagosklonny, M. V. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle Georget. Tex. 6, 70\u201374 (2007).","journal-title":"Cell Cycle Georget. Tex."},{"key":"1104_CR56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/15384101.2018.1559557","volume":"18","author":"D Sinha","year":"2019","unstructured":"Sinha, D., Duijf, P. H. G. & Khanna, K. K. Mitotic slippage: an old tale with a new twist. Cell Cycle 18, 7\u201315 (2019).","journal-title":"Cell Cycle"},{"key":"1104_CR57","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1146\/annurev.cb.04.110188.003351","volume":"4","author":"KF Sullivan","year":"1988","unstructured":"Sullivan, K. F. Structure and utilization of tubulin isotypes. Annu. Rev. Cell Biol. 4, 687\u2013716 (1988).","journal-title":"Annu. Rev. Cell Biol."},{"key":"1104_CR58","first-page":"O1","volume":"1471","author":"CA Burkhart","year":"2001","unstructured":"Burkhart, C. A., Kavallaris, M. & Band Horwitz, S. The role of \u03b2-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta 1471, O1\u2013O9 (2001).","journal-title":"Biochim. Biophys. Acta"},{"key":"1104_CR59","doi-asserted-by":"publisher","first-page":"11358","DOI":"10.1073\/pnas.91.24.11358","volume":"91","author":"D Panda","year":"1994","unstructured":"Panda, D., Miller, H. P., Banerjee, A., Ludue\u00f1a, R. F. & Wilson, L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc. Natl Acad. Sci. USA 91, 11358\u201311362 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1247\/csf.18.173","volume":"18","author":"Q Lu","year":"1993","unstructured":"Lu, Q. & Luduena, R. F. Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct. Funct. 18, 173\u2013182 (1993).","journal-title":"Cell Struct. Funct."},{"key":"1104_CR61","doi-asserted-by":"publisher","first-page":"188607","DOI":"10.1016\/j.bbcan.2021.188607","volume":"1876","author":"A Kanakkanthara","year":"2021","unstructured":"Kanakkanthara, A. & Miller, J. H. \u03b2III-tubulin overexpression in cancer: causes, consequences, and potential therapies. Biochim. Biophys. Acta Rev. Cancer 1876, 188607 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1104_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cm.10132","volume":"56","author":"M Hari","year":"2003","unstructured":"Hari, M., Yang, H., Zeng, C., Canizales, M. & Cabral, F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil. Cytoskeleton 56, 45\u201356 (2003).","journal-title":"Cell Motil. Cytoskeleton"},{"key":"1104_CR63","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1111\/j.1742-4658.2006.05340.x","volume":"273","author":"M Magnani","year":"2006","unstructured":"Magnani, M. et al. The \u03b2I\/\u03b2III-tubulin isoforms and their complexes with antimitotic agents. docking and molecular dynamics studies. FEBS J. 273, 3301\u20133310 (2006).","journal-title":"FEBS J."},{"key":"1104_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222510","volume":"14","author":"L Maahs","year":"2019","unstructured":"Maahs, L. et al. Class III \u03b2-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer. PLoS ONE 14, e0222510 (2019).","journal-title":"PLoS ONE"},{"key":"1104_CR65","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/sj.bjc.6605245","volume":"101","author":"S Terry","year":"2009","unstructured":"Terry, S. et al. Increased expression of class III \u03b2-tubulin in castration-resistant human prostate cancer. Br. J. Cancer 101, 951\u2013956 (2009).","journal-title":"Br. J. Cancer"},{"key":"1104_CR66","doi-asserted-by":"publisher","first-page":"9253","DOI":"10.1158\/0008-5472.CAN-10-1447","volume":"70","author":"G Ploussard","year":"2010","unstructured":"Ploussard, G. et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res. 70, 9253\u20139264 (2010).","journal-title":"Cancer Res."},{"key":"1104_CR67","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1042\/CBI20090030","volume":"34","author":"T Hara","year":"2010","unstructured":"Hara, T. et al. A mutation in \u03b2-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. Cell Biol. Int. 34, 177\u2013184 (2010).","journal-title":"Cell Biol. Int."},{"key":"1104_CR68","doi-asserted-by":"publisher","first-page":"17118","DOI":"10.1074\/jbc.272.27.17118","volume":"272","author":"P Giannakakou","year":"1997","unstructured":"Giannakakou, P. et al. Paclitaxel-resistant human ovarian cancer cells have mutant \u03b2-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272, 17118\u201317125 (1997).","journal-title":"J. Biol. Chem."},{"key":"1104_CR69","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1073\/pnas.040546297","volume":"97","author":"P Giannakakou","year":"2000","unstructured":"Giannakakou, P. et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl Acad. Sci. USA 97, 2904\u20132909 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR70","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/iub.25","volume":"60","author":"E Pasquier","year":"2008","unstructured":"Pasquier, E. & Kavallaris, M. Microtubules: a dynamic target in cancer therapy. IUBMB Life 60, 165\u2013170 (2008).","journal-title":"IUBMB Life"},{"key":"1104_CR71","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S1470-2045(04)01411-1","volume":"5","author":"HK Berrieman","year":"2004","unstructured":"Berrieman, H. K., Lind, M. J. & Cawkwell, L. Do \u03b2-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol. 5, 158\u2013164 (2004).","journal-title":"Lancet Oncol."},{"key":"1104_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14513","volume":"103","author":"L Zhou","year":"2024","unstructured":"Zhou, L. et al. Systematic profiling of taxol resistance and sensitivity to tubulin missence mutations at molecular and cellular levels. Chem. Biol. Drug. Des. 103, e14513 (2024).","journal-title":"Chem. Biol. Drug. Des."},{"key":"1104_CR73","first-page":"3","volume":"1","author":"L He","year":"2001","unstructured":"He, L., Yang, C. P. & Horwitz, S. B. Mutations in \u03b2-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol. Cancer Ther. 1, 3\u201310 (2001).","journal-title":"Mol. Cancer Ther."},{"key":"1104_CR74","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/cancers14010051","volume":"14","author":"D Westaby","year":"2021","unstructured":"Westaby, D. et al. Targeting the intrinsic apoptosis pathway: a window of opportunity for prostate cancer. Cancers 14, 51 (2021).","journal-title":"Cancers"},{"key":"1104_CR75","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/42867","volume":"387","author":"JC Reed","year":"1997","unstructured":"Reed, J. C. Double identity for proteins of the Bcl-2 family. Nature 387, 773\u2013776 (1997).","journal-title":"Nature"},{"key":"1104_CR76","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","volume":"74","author":"ZN Oltvai","year":"1993","unstructured":"Oltvai, Z. N., Milliman, C. L. & Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609\u2013619 (1993).","journal-title":"Cell"},{"key":"1104_CR77","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/374733a0","volume":"374","author":"T Chittenden","year":"1995","unstructured":"Chittenden, T. et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374, 733\u2013736 (1995).","journal-title":"Nature"},{"key":"1104_CR78","first-page":"6940","volume":"52","author":"TJ McDonnell","year":"1992","unstructured":"McDonnell, T. J. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940\u20136944 (1992).","journal-title":"Cancer Res."},{"key":"1104_CR79","first-page":"4438","volume":"55","author":"AJ Raffo","year":"1995","unstructured":"Raffo, A. J. et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55, 4438\u20134445 (1995).","journal-title":"Cancer Res."},{"key":"1104_CR80","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1073\/pnas.92.10.4507","volume":"92","author":"S Haldar","year":"1995","unstructured":"Haldar, S., Jena, N. & Croce, C. M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl Acad. Sci. USA 92, 4507\u20134511 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR81","first-page":"1567","volume":"148","author":"M Krajewska","year":"1996","unstructured":"Krajewska, M. et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148, 1567\u20131576 (1996).","journal-title":"Am. J. Pathol."},{"key":"1104_CR82","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1124\/mol.64.1.51","volume":"64","author":"C Ferlini","year":"2003","unstructured":"Ferlini, C. et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol. Pharmacol. 64, 51\u201358 (2003).","journal-title":"Mol. Pharmacol."},{"key":"1104_CR83","first-page":"259","volume":"13","author":"Y Inoue","year":"2005","unstructured":"Inoue, Y. et al. Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol. Rep. 13, 259\u2013264 (2005).","journal-title":"Oncol. Rep."},{"key":"1104_CR84","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.eururo.2020.10.001","volume":"79","author":"V Ruiz de Porras","year":"2021","unstructured":"Ruiz de Porras, V. et al. Taxane-induced attenuation of the CXCR2\/BCL-2 axis sensitizes prostate cancer to platinum-based treatment. Eur. Urol. 79, 722\u2013733 (2021).","journal-title":"Eur. Urol."},{"key":"1104_CR85","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/annonc\/mdn784","volume":"20","author":"CN Sternberg","year":"2009","unstructured":"Sternberg, C. N. et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann. Oncol. 20, 1264\u20131269 (2009).","journal-title":"Ann. Oncol."},{"key":"1104_CR86","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/annonc\/mdr555","volume":"23","author":"G Sonpavde","year":"2012","unstructured":"Sonpavde, G. et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann. Oncol. 23, 1803\u20131808 (2012).","journal-title":"Ann. Oncol."},{"key":"1104_CR87","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1464-410X.2008.07618.x","volume":"102","author":"RD Sowery","year":"2008","unstructured":"Sowery, R. D. et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 102, 389\u2013397 (2008).","journal-title":"BJU Int."},{"key":"1104_CR88","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/S1470-2045(17)30605-8","volume":"18","author":"TM Beer","year":"2017","unstructured":"Beer, T. M. et al. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet Oncol. 18, 1532\u20131542 (2017).","journal-title":"Lancet Oncol."},{"key":"1104_CR89","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41585-020-0298-8","volume":"17","author":"M Carceles-Cordon","year":"2020","unstructured":"Carceles-Cordon, M. et al. Cellular rewiring in lethal prostate cancer: the architect of drug resistance. Nat. Rev. Urol. 17, 292\u2013307 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"1104_CR90","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/annonc\/mds119","volume":"23","author":"J Mezynski","year":"2012","unstructured":"Mezynski, J. et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann. Oncol. 23, 2943\u20132947 (2012).","journal-title":"Ann. Oncol."},{"key":"1104_CR91","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","volume":"71","author":"MS Darshan","year":"2011","unstructured":"Darshan, M. S. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71, 6019\u20136029 (2011).","journal-title":"Cancer Res."},{"key":"1104_CR92","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1158\/1078-0432.CCR-06-2701","volume":"13","author":"DR Shaffer","year":"2007","unstructured":"Shaffer, D. R. et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 13, 2023\u20132029 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR93","doi-asserted-by":"publisher","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","volume":"70","author":"M-L Zhu","year":"2010","unstructured":"Zhu, M.-L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992\u20138002 (2010).","journal-title":"Cancer Res."},{"key":"1104_CR94","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4103\/aja.aja_37_18","volume":"21","author":"S Bai","year":"2019","unstructured":"Bai, S., Zhang, B. Y. & Dong, Y. Impact of taxanes on androgen receptor signaling. Asian J. Androl. 21, 249\u2013252 (2019).","journal-title":"Asian J. Androl."},{"key":"1104_CR95","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003088-199936020-00002","volume":"36","author":"SJ Clarke","year":"1999","unstructured":"Clarke, S. J. & Rivory, L. P. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 36, 99\u2013114 (1999).","journal-title":"Clin. Pharmacokinet."},{"key":"1104_CR96","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/cas.12647","volume":"106","author":"H Kenmotsu","year":"2015","unstructured":"Kenmotsu, H. & Tanigawara, Y. Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the western dose. Cancer Sci. 106, 497\u2013504 (2015).","journal-title":"Cancer Sci."},{"key":"1104_CR97","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1158\/1078-0432.CCR-14-1358","volume":"21","author":"R de Leeuw","year":"2015","unstructured":"de Leeuw, R. et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin. Cancer Res. 21, 795\u2013807 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR98","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/pros.21004","volume":"69","author":"K Kuroda","year":"2009","unstructured":"Kuroda, K. et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 69, 1579\u20131585 (2009).","journal-title":"Prostate"},{"key":"1104_CR99","doi-asserted-by":"publisher","first-page":"8386","DOI":"10.1158\/0008-5472.CAN-09-1504","volume":"69","author":"L Gan","year":"2009","unstructured":"Gan, L. et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 69, 8386\u20138394 (2009).","journal-title":"Cancer Res."},{"key":"1104_CR100","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5306\/wjco.v6.i4.64","volume":"6","author":"R Shameem","year":"2015","unstructured":"Shameem, R., Hamid, M. S., Xu, K. Y. & Wu, S. Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World J. Clin. Oncol. 6, 64\u201372 (2015).","journal-title":"World J. Clin. Oncol."},{"key":"1104_CR101","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187\u20131197 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR102","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.eururo.2014.04.015","volume":"68","author":"N Al Nakouzi","year":"2015","unstructured":"Al Nakouzi, N. et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur. Urol. 68, 228\u2013235 (2015).","journal-title":"Eur. Urol."},{"key":"1104_CR103","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.3390\/cancers13184522","volume":"13","author":"C Cattrini","year":"2021","unstructured":"Cattrini, C. et al. Optimal sequencing and predictive biomarkers in patients with advanced prostate cancer. Cancers 13, 4522 (2021).","journal-title":"Cancers"},{"key":"1104_CR104","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121\u2013131 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR105","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR106","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13\u201324 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR107","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ejca.2022.07.011","volume":"173","author":"C Ciccarese","year":"2022","unstructured":"Ciccarese, C. et al. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: a meta-analysis. Eur. J. Cancer 173, 276\u2013284 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1104_CR108","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/cancers16183187","volume":"16","author":"W-A Kwon","year":"2024","unstructured":"Kwon, W.-A., Song, Y. S. & Lee, M.-K. Strategic advances in combination therapy for metastatic castration-sensitive prostate cancer: current insights and future perspectives. Cancers 16, 3187 (2024).","journal-title":"Cancers"},{"key":"1104_CR109","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1097\/JU.0000000000002121","volume":"206","author":"CJ Ryan","year":"2021","unstructured":"Ryan, C. J. et al. Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States. J. Urol. 206, 1420\u20131429 (2021).","journal-title":"J. Urol."},{"key":"1104_CR110","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Guo, Z. et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305\u20132313 (2009).","journal-title":"Cancer Res."},{"key":"1104_CR111","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16\u201322 (2009).","journal-title":"Cancer Res."},{"key":"1104_CR112","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1172\/JCI41824","volume":"120","author":"S Sun","year":"2010","unstructured":"Sun, S. et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715\u20132730 (2010).","journal-title":"J. Clin. Invest."},{"key":"1104_CR113","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/0008-5472.CAN-13-2876","volume":"74","author":"M Thadani-Mulero","year":"2014","unstructured":"Thadani-Mulero, M. et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 74, 2270\u20132282 (2014).","journal-title":"Cancer Res."},{"key":"1104_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2012.02.019","volume":"358","author":"L Clinckemalie","year":"2012","unstructured":"Clinckemalie, L., Vanderschueren, D., Boonen, S. & Claessens, F. The hinge region in androgen receptor control. Mol. Cell. Endocrinol. 358, 1\u20138 (2012).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1104_CR115","doi-asserted-by":"publisher","first-page":"13115","DOI":"10.1016\/S0021-9258(17)36806-0","volume":"269","author":"ZX Zhou","year":"1994","unstructured":"Zhou, Z. X., Sar, M., Simental, J. A., Lane, M. V. & Wilson, E. M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J. Biol. Chem. 269, 13115\u201313123 (1994).","journal-title":"J. Biol. Chem."},{"key":"1104_CR116","doi-asserted-by":"publisher","DOI":"10.1621\/nrs.06008","volume":"6","author":"F Claessens","year":"2008","unstructured":"Claessens, F. et al. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl. Recept. Signal. 6, e008 (2008).","journal-title":"Nucl. Recept. Signal."},{"key":"1104_CR117","doi-asserted-by":"publisher","first-page":"23358","DOI":"10.18632\/oncotarget.4396","volume":"6","author":"G Zhang","year":"2015","unstructured":"Zhang, G. et al. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. Oncotarget 6, 23358\u201323371 (2015).","journal-title":"Oncotarget"},{"key":"1104_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53280-5","volume":"9","author":"M Shim","year":"2019","unstructured":"Shim, M., Kim, Y., Park, Y. & Ahn, H. Taxane-based chemotherapy induced androgen receptor splice variant 7 in patients with castration-resistant prostate cancer: a tissue-based analysis. Sci. Rep. 9, 16794 (2019).","journal-title":"Sci. Rep."},{"key":"1104_CR119","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.18632\/oncotarget.1802","volume":"5","author":"B Cao","year":"2014","unstructured":"Cao, B. et al. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5, 1646\u20131656 (2014).","journal-title":"Oncotarget"},{"key":"1104_CR120","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.eururo.2015.07.007","volume":"68","author":"W Onstenk","year":"2015","unstructured":"Onstenk, W. et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur. Urol. 68, 939\u2013945 (2015).","journal-title":"Eur. Urol."},{"key":"1104_CR121","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher, H. I. et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2, 1441\u20131449 (2016).","journal-title":"JAMA Oncol."},{"key":"1104_CR122","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","volume":"1","author":"ES Antonarakis","year":"2015","unstructured":"Antonarakis, E. S. et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 1, 582\u2013591 (2015).","journal-title":"JAMA Oncol."},{"key":"1104_CR123","first-page":"PO.20.00200","volume":"4","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong, A. J. et al. Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer. JCO Precis. Oncol. 4, PO.20.00200 (2020).","journal-title":"JCO Precis. Oncol."},{"key":"1104_CR124","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/cells9010203","volume":"9","author":"M Mar\u00edn-Aguilera","year":"2020","unstructured":"Mar\u00edn-Aguilera, M. et al. Androgen receptor and its splicing variant 7 expression in peripheral blood mononuclear cells and in circulating tumor cells in metastatic castration-resistant prostate cancer. Cells 9, 203 (2020).","journal-title":"Cells"},{"key":"1104_CR125","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1172\/JCI122819","volume":"129","author":"A Sharp","year":"2019","unstructured":"Sharp, A. et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J. Clin. Invest. 129, 192\u2013208 (2019).","journal-title":"J. Clin. Invest."},{"key":"1104_CR126","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1158\/1078-0432.CCR-18-0320","volume":"25","author":"ST Tagawa","year":"2019","unstructured":"Tagawa, S. T. et al. Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY. Clin. Cancer Res. 25, 1880\u20131888 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR127","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644\u2013648 (2005).","journal-title":"Science"},{"key":"1104_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6548","volume":"5","author":"G Galletti","year":"2014","unstructured":"Galletti, G. et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat. Commun. 5, 5548 (2014).","journal-title":"Nat. Commun."},{"key":"1104_CR129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021650","volume":"6","author":"O Leshem","year":"2011","unstructured":"Leshem, O. et al. TMPRSS2\/ERG promotes epithelial to mesenchymal transition through the ZEB1\/ZEB2 axis in a prostate cancer model. PLoS ONE 6, e21650 (2011).","journal-title":"PLoS ONE"},{"key":"1104_CR130","doi-asserted-by":"publisher","first-page":"289.e1","DOI":"10.1016\/j.urolonc.2018.12.007","volume":"37","author":"Z K\u00fcronya","year":"2019","unstructured":"K\u00fcronya, Z. et al. ERG expression can predict the outcome of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. Urol. Oncol. 37, 289.e1\u2013289.e9 (2019).","journal-title":"Urol. Oncol."},{"key":"1104_CR131","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.euo.2024.06.015","volume":"8","author":"S Rajpar","year":"2025","unstructured":"Rajpar, S. et al. The benefit of combining docetaxel with androgen deprivation therapy in localized and metastatic hormone-sensitive prostate cancer is predicted by ERG expression: an analysis of two GETUG phase 3 trials. Eur. Urol. Oncol. 8, 296\u2013305 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR132","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.eururo.2016.02.034","volume":"70","author":"\u00d2 Reig","year":"2016","unstructured":"Reig, \u00d2 et al. TMPRSS2-ERG in blood and docetaxel resistance in metastatic castration-resistant prostate cancer. Eur. Urol. 70, 709\u2013713 (2016).","journal-title":"Eur. Urol."},{"key":"1104_CR133","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/s41591-024-03204-2","volume":"30","author":"B De Laere","year":"2024","unstructured":"De Laere, B. et al. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. Nat. Med. 30, 3291\u20133302 (2024).","journal-title":"Nat. Med."},{"key":"1104_CR134","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3390\/cells9112342","volume":"9","author":"DJ Turnham","year":"2020","unstructured":"Turnham, D. J., Bullock, N., Dass, M. S., Staffurth, J. N. & Pearson, H. B. The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 9, 2342 (2020).","journal-title":"Cells"},{"key":"1104_CR135","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"1104_CR136","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili, T. et al. Clinical implications of PTEN loss in prostate cancer. Nat. Rev. Urol. 15, 222\u2013234 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"1104_CR137","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575\u2013586 (2011).","journal-title":"Cancer Cell"},{"issue":"Suppl 1","key":"1104_CR138","first-page":"S60","volume":"82","author":"AD Choudhury","year":"2022","unstructured":"Choudhury, A. D. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications. Prostate 82 (Suppl 1), S60\u2013S72 (2022).","journal-title":"Prostate"},{"key":"1104_CR139","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1158\/1535-7163.MCT-13-0208","volume":"12","author":"Y Zhu","year":"2013","unstructured":"Zhu, Y. et al. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol. Cancer Ther. 12, 1829\u20131836 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"1104_CR140","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/jcb.25091","volume":"116","author":"Z Liu","year":"2015","unstructured":"Liu, Z., Zhu, G., Getzenberg, R. H. & Veltri, R. W. The upregulation of PI3K\/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer. J. Cell. Biochem. 116, 1341\u20131349 (2015).","journal-title":"J. Cell. Biochem."},{"key":"1104_CR141","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.juro.2011.02.016","volume":"185","author":"T Kosaka","year":"2011","unstructured":"Kosaka, T. et al. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J. Urol. 185, 2376\u20132381 (2011).","journal-title":"J. Urol."},{"key":"1104_CR142","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.juro.2013.07.101","volume":"191","author":"Y Yasumizu","year":"2014","unstructured":"Yasumizu, Y. et al. Dual PI3K\/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J. Urol. 191, 227\u2013234 (2014).","journal-title":"J. Urol."},{"key":"1104_CR143","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","volume":"11","author":"BR Davies","year":"2012","unstructured":"Davies, B. R. et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther. 11, 873\u2013887 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"1104_CR144","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1535-7163.MCT-14-0406","volume":"14","author":"U Hancox","year":"2015","unstructured":"Hancox, U. et al. Inhibition of PI3K\u03b2 signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. Mol. Cancer Ther. 14, 48\u201358 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"1104_CR145","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41416-024-02614-w","volume":"130","author":"C Eberlein","year":"2024","unstructured":"Eberlein, C. et al. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br. J. Cancer 130, 1377\u20131387 (2024).","journal-title":"Br. J. Cancer"},{"key":"1104_CR146","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.20.01576","volume":"39","author":"SJ Crabb","year":"2021","unstructured":"Crabb, S. J. et al. Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID). J. Clin. Oncol. 39, 190\u2013201 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR147","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.eururo.2022.05.019","volume":"82","author":"SJ Crabb","year":"2022","unstructured":"Crabb, S. J. et al. Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial. Eur. Urol. 82, 512\u2013515 (2022).","journal-title":"Eur. Urol."},{"key":"1104_CR148","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euo.2018.02.006","volume":"1","author":"P Rescigno","year":"2018","unstructured":"Rescigno, P. et al. Docetaxel treatment in PTEN- and ERG-aberrant metastatic prostate cancers. Eur. Urol. Oncol. 1, 71\u201377 (2018).","journal-title":"Eur. Urol. Oncol."},{"key":"1104_CR149","unstructured":"Update on CAPItello-280 phase III trial of truqap in metastatic castration-resistant prostate cancer. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/update-on-capitello-280-phase-iii-trial.html (2025)."},{"key":"1104_CR150","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0378-4274(90)90208-4","volume":"51","author":"L von Meyerinck","year":"1990","unstructured":"von Meyerinck, L., Hufnagel, B., Schmoldt, A. & Benthe, H. F. Investigations on benzyltoluenes. I. Induction of microsomal cytochrome P-450 and UDP-glucuronosyltransferase by tetrachlorobenzyltoluenes and by the condensate. Toxicol. Lett. 51, 163\u2013174 (1990).","journal-title":"Toxicol. Lett."},{"key":"1104_CR151","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/0008-5472.CAN-16-1589","volume":"77","author":"C Thangavel","year":"2017","unstructured":"Thangavel, C. et al. RB loss promotes prostate cancer metastasis. Cancer Res. 77, 982\u2013995 (2017).","journal-title":"Cancer Res."},{"key":"1104_CR152","doi-asserted-by":"publisher","first-page":"7889","DOI":"10.1158\/0008-5472.CAN-06-0486","volume":"66","author":"Z Zhou","year":"2006","unstructured":"Zhou, Z. et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 66, 7889\u20137898 (2006).","journal-title":"Cancer Res."},{"key":"1104_CR153","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1158\/0008-5472.CAN-06-4424","volume":"67","author":"A Sharma","year":"2007","unstructured":"Sharma, A. et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res. 67, 6192\u20136203 (2007).","journal-title":"Cancer Res."},{"key":"1104_CR154","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR155","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrc3216","volume":"12","author":"AL Manning","year":"2012","unstructured":"Manning, A. L. & Dyson, N. J. RB: mitotic implications of a tumour suppressor. Nat. Rev. Cancer 12, 220\u2013226 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1104_CR156","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","volume":"27","author":"PL Palmbos","year":"2021","unstructured":"Palmbos, P. L. et al. A randomized phase II study of androgen deprivation therapy with or without Palbociclib in RB-positive metastatic hormone-sensitive prostate cancer. Clin. Cancer Res. 27, 3017\u20133027 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR157","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/pcan.2010.20","volume":"13","author":"H Chen","year":"2010","unstructured":"Chen, H. et al. 8q24 allelic imbalance and MYC gene copy number in primary prostate cancer. Prostate Cancer Prostatic Dis. 13, 238\u2013243 (2010).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1104_CR158","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.humpath.2013.01.012","volume":"44","author":"G Fromont","year":"2013","unstructured":"Fromont, G. et al. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. Hum. Pathol. 44, 1617\u20131623 (2013).","journal-title":"Hum. Pathol."},{"key":"1104_CR159","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2353\/ajpath.2006.060316","volume":"169","author":"TA Dunn","year":"2006","unstructured":"Dunn, T. A. et al. A novel role of myosin VI in human prostate cancer. Am. J. Pathol. 169, 1843\u20131854 (2006).","journal-title":"Am. J. Pathol."},{"key":"1104_CR160","first-page":"1535","volume":"46","author":"WH Fleming","year":"1986","unstructured":"Fleming, W. H. et al. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res. 46, 1535\u20131538 (1986).","journal-title":"Cancer Res."},{"key":"1104_CR161","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/modpathol.2008.111","volume":"21","author":"B Gurel","year":"2008","unstructured":"Gurel, B. et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 21, 1156\u20131167 (2008).","journal-title":"Mod. Pathol."},{"key":"1104_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063563","volume":"8","author":"L Gao","year":"2013","unstructured":"Gao, L. et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS ONE 8, e63563 (2013).","journal-title":"PLoS ONE"},{"key":"1104_CR163","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1002\/cncr.27689","volume":"118","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis, E. S. et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 118, 6063\u20136071 (2012).","journal-title":"Cancer"},{"key":"1104_CR164","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/1541-7786.MCR-13-0029-T","volume":"11","author":"K Hatano","year":"2013","unstructured":"Hatano, K. et al. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1\/2 and c-Myc. Mol. Cancer Res. 11, 1088\u20131100 (2013).","journal-title":"Mol. Cancer Res."},{"key":"1104_CR165","doi-asserted-by":"publisher","first-page":"109631","DOI":"10.1016\/j.cellsig.2020.109631","volume":"72","author":"X Lei","year":"2020","unstructured":"Lei, X. et al. HMGB1 release promotes paclitaxel resistance in castration-resistant prostate cancer cells via activating c-Myc expression. Cell. Signal. 72, 109631 (2020).","journal-title":"Cell. Signal."},{"key":"1104_CR166","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487\u2013495 (2011).","journal-title":"Cancer Discov."},{"key":"1104_CR167","doi-asserted-by":"publisher","first-page":"669","DOI":"10.18632\/oncotarget.327","volume":"2","author":"CM Koh","year":"2011","unstructured":"Koh, C. M. et al. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2, 669\u2013683 (2011).","journal-title":"Oncotarget"},{"key":"1104_CR168","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran, H. et al. A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin. Cancer Res. 25, 43\u201351 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR169","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154\u20132164 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR170","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR171","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"1104_CR172","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"1104_CR173","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785\u20133790 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR174","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR175","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain, M. et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl. J. Med. 383, 2345\u20132357 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR176","first-page":"862","volume":"38","author":"K Murali","year":"2018","unstructured":"Murali, K., Makker, V., Lynch, J. & Banerjee, S. From burnout to resilience: an update for oncologists. Am. Soc. Clin. Oncol. 38, 862\u2013872 (2018).","journal-title":"Am. Soc. Clin. Oncol."},{"key":"1104_CR177","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo, J. et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial. J. Clin. Oncol. 42, 571\u2013583 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR178","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.10950","volume":"4","author":"CJD Wallis","year":"2021","unstructured":"Wallis, C. J. D. et al. Olaparib vs cabazitaxel in metastatic castration-resistant prostate cancer. JAMA Netw. Open. 4, e2110950 (2021).","journal-title":"JAMA Netw. Open."},{"key":"1104_CR179","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi, K. et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N. Engl. J. Med. 388, 719\u2013732 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR180","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/pros.24236","volume":"81","author":"AO Sokolova","year":"2021","unstructured":"Sokolova, A. O. et al. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Prostate 81, 1382\u20131389 (2021).","journal-title":"Prostate"},{"key":"1104_CR181","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1158\/1078-0432.CCR-22-3394","volume":"29","author":"J Hwang","year":"2023","unstructured":"Hwang, J. et al. Metastatic prostate cancers with BRCA2 versus ATM mutations exhibit divergent molecular features and clinical outcomes. Clin. Cancer Res. 29, 2702\u20132713 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR182","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/pros.24454","volume":"83","author":"CT Su","year":"2023","unstructured":"Su, C. T. et al. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. Prostate 83, 227\u2013236 (2023).","journal-title":"Prostate"},{"key":"1104_CR183","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","volume":"8","author":"M Annala","year":"2018","unstructured":"Annala, M. et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 8, 444\u2013457 (2018).","journal-title":"Cancer Discov."},{"key":"1104_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04897-x","volume":"7","author":"C Nientiedt","year":"2017","unstructured":"Nientiedt, C. et al. Mutations in BRCA2 and taxane resistance in prostate cancer. Sci. Rep. 7, 4574 (2017).","journal-title":"Sci. Rep."},{"key":"1104_CR185","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1158\/1078-0432.CCR-15-1050","volume":"22","author":"NM Corcoran","year":"2016","unstructured":"Corcoran, N. M., Clarkson, M. J., Stuchbery, R. & Hovens, C. M. Molecular pathways: targeting DNA repair pathway defects enriched in metastasis. Clin. Cancer Res. 22, 3132\u20133137 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR186","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia, J. et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645\u2013651 (2018).","journal-title":"Nat. Genet."},{"key":"1104_CR187","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/onc.2013.85","volume":"33","author":"M Sung","year":"2014","unstructured":"Sung, M. & Giannakakou, P. BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene 33, 1418\u20131428 (2014).","journal-title":"Oncogene"},{"key":"1104_CR188","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615\u2013627 (2002).","journal-title":"Annu. Rev. Med."},{"key":"1104_CR189","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1073\/pnas.94.8.4028","volume":"94","author":"AH Schinkel","year":"1997","unstructured":"Schinkel, A. H. et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl Acad. Sci. USA 94, 4028\u20134033 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR190","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/PL00000912","volume":"58","author":"T Litman","year":"2001","unstructured":"Litman, T., Druley, T. E., Stein, W. D. & Bates, S. E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58, 931\u2013959 (2001).","journal-title":"Cell. Mol. Life Sci."},{"key":"1104_CR191","doi-asserted-by":"publisher","first-page":"16185","DOI":"10.18632\/oncotarget.24609","volume":"9","author":"K Machioka","year":"2018","unstructured":"Machioka, K. et al. Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget 9, 16185\u201316196 (2018).","journal-title":"Oncotarget"},{"key":"1104_CR192","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ccr.2012.07.016","volume":"22","author":"J Domingo-Domenech","year":"2012","unstructured":"Domingo-Domenech, J. et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22, 373\u2013388 (2012).","journal-title":"Cancer Cell"},{"key":"1104_CR193","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1535-7163.MCT-17-0179","volume":"16","author":"AP Lombard","year":"2017","unstructured":"Lombard, A. P. et al. ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer. Mol. Cancer Ther. 16, 2257\u20132266 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"1104_CR194","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1021\/acs.jmedchem.7b01457","volume":"61","author":"D Waghray","year":"2018","unstructured":"Waghray, D. & Zhang, Q. Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J. Med. Chem. 61, 5108\u20135121 (2018).","journal-title":"J. Med. Chem."},{"key":"1104_CR195","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452\u2013464 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1104_CR196","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4103\/0976-500X.119704","volume":"4","author":"A Abidi","year":"2013","unstructured":"Abidi, A. Cabazitaxel: a novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J. Pharmacol. Pharmacother. 4, 230\u2013237 (2013).","journal-title":"J. Pharmacol. Pharmacother."},{"key":"1104_CR197","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-14-0155","volume":"14","author":"GE Duran","year":"2015","unstructured":"Duran, G. E. et al. Mechanisms of resistance to cabazitaxel. Mol. Cancer Ther. 14, 193\u2013201 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"1104_CR198","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/cas.13876","volume":"110","author":"A Natsagdorj","year":"2019","unstructured":"Natsagdorj, A. et al. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. Cancer Sci. 110, 279\u2013288 (2019).","journal-title":"Cancer Sci."},{"key":"1104_CR199","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00345-014-1469-0","volume":"33","author":"M Saupe","year":"2015","unstructured":"Saupe, M. et al. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity. World J. Urol. 33, 1481\u20131486 (2015).","journal-title":"World J. Urol."},{"key":"1104_CR200","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1073\/pnas.84.1.265","volume":"84","author":"AT Fojo","year":"1987","unstructured":"Fojo, A. T. et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl Acad. Sci. USA 84, 265\u2013269 (1987).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1104_CR201","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0304-3835(99)00384-5","volume":"150","author":"K Kawai","year":"2000","unstructured":"Kawai, K. et al. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett. 150, 147\u2013153 (2000).","journal-title":"Cancer Lett."},{"key":"1104_CR202","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3892\/ol.2017.6357","volume":"14","author":"Y-F Li","year":"2017","unstructured":"Li, Y.-F. et al. Targeting MRP4 expression by anti-androgen treatment reverses MRP4-mediated docetaxel resistance in castration-resistant prostate cancer. Oncol. Lett. 14, 1748\u20131756 (2017).","journal-title":"Oncol. Lett."},{"key":"1104_CR203","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.7150\/ijbs.99716","volume":"20","author":"L Li","year":"2024","unstructured":"Li, L. et al. Tumor ABCC4-mediated release of PGE2 induces CD8+ T cell dysfunction and impairs PD-1 blockade in prostate cancer. Int. J. Biol. Sci. 20, 4424\u20134437 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"1104_CR204","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bcp.2014.05.023","volume":"91","author":"L Cheung","year":"2014","unstructured":"Cheung, L. et al. High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochem. Pharmacol. 91, 97\u2013108 (2014).","journal-title":"Biochem. Pharmacol."},{"key":"1104_CR205","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/medicina58060695","volume":"58","author":"E Becerra","year":"2022","unstructured":"Becerra, E., Berumen, L., Soto-Ontiveros, V. & Garc\u00eda-Alcocer, G. Specific MRP4 inhibitor ceefourin-1 enhances apoptosis induced by 6-mercaptopurine in jurkat leukemic cells, but not in normal lymphoblast cell line CRL-1991. Medicinas 58, 695 (2022).","journal-title":"Medicinas"},{"key":"1104_CR206","first-page":"699","volume":"76","author":"KG Leong","year":"2008","unstructured":"Leong, K. G. & Gao, W.-Q. The Notch pathway in prostate development and cancer. Differ. Res. Biol. Divers. 76, 699\u2013716 (2008).","journal-title":"Differ. Res. Biol. Divers."},{"key":"1104_CR207","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ydbio.2005.11.009","volume":"290","author":"X-D Wang","year":"2006","unstructured":"Wang, X.-D. et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev. Biol. 290, 66\u201380 (2006).","journal-title":"Dev. Biol."},{"key":"1104_CR208","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nature02962","volume":"431","author":"SS Karhadkar","year":"2004","unstructured":"Karhadkar, S. S. et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431, 707\u2013712 (2004).","journal-title":"Nature"},{"key":"1104_CR209","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ccell.2021.02.005","volume":"39","author":"E Pujadas","year":"2021","unstructured":"Pujadas, E. & Cordon-Cardo, C. The human leukocyte antigen as a candidate tumor suppressor. Cancer Cell 39, 586\u2013589 (2021).","journal-title":"Cancer Cell"},{"key":"1104_CR210","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1158\/1078-0432.CCR-15-0242","volume":"21","author":"D Cui","year":"2015","unstructured":"Cui, D. et al. Notch pathway inhibition using PF-03084014, a \u03b3-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer. Clin. Cancer Res. 21, 4619\u20134629 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR211","doi-asserted-by":"publisher","first-page":"30363","DOI":"10.18632\/oncotarget.25744","volume":"9","author":"CK Cajigas-Du Ross","year":"2018","unstructured":"Cajigas-Du Ross, C. K. et al. RNA sequencing reveals upregulation of a transcriptomic program associated with stemness in metastatic prostate cancer cells selected for taxane resistance. Oncotarget 9, 30363\u201330384 (2018).","journal-title":"Oncotarget"},{"key":"1104_CR212","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/1535-7163.MCT-13-0775","volume":"13","author":"M Mar\u00edn-Aguilera","year":"2014","unstructured":"Mar\u00edn-Aguilera, M. et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol. Cancer Ther. 13, 1270\u20131284 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"1104_CR213","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/1878-0261.12030","volume":"11","author":"K Hanrahan","year":"2017","unstructured":"Hanrahan, K. et al. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer. Mol. Oncol. 11, 251\u2013265 (2017).","journal-title":"Mol. Oncol."},{"key":"1104_CR214","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14296-y","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Identification of a Zeb1 expressing basal stem cell subpopulation in the prostate. Nat. Commun. 11, 706 (2020).","journal-title":"Nat. Commun."},{"key":"1104_CR215","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1158\/1078-0432.CCR-15-1613","volume":"21","author":"T Zhang","year":"2015","unstructured":"Zhang, T. & Armstrong, A. J. Docetaxel resistance in prostate cancer: taking it up a notch. Clin. Cancer Res. 21, 4505\u20134507 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR216","doi-asserted-by":"publisher","first-page":"104182","DOI":"10.18632\/oncotarget.22115","volume":"8","author":"AE Ross","year":"2017","unstructured":"Ross, A. E. et al. Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. Oncotarget 8, 104182\u2013104192 (2017).","journal-title":"Oncotarget"},{"key":"1104_CR217","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00280-016-3191-7","volume":"78","author":"BL Maughan","year":"2016","unstructured":"Maughan, B. L. et al. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 78, 1297\u20131304 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1104_CR218","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.biopha.2017.10.163","volume":"97","author":"G Zhang","year":"2018","unstructured":"Zhang, G. et al. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1. Biomed. Pharmacother. Biomedecine Pharmacother. 97, 736\u2013744 (2018).","journal-title":"Biomed. Pharmacother. Biomedecine Pharmacother."},{"key":"1104_CR219","doi-asserted-by":"publisher","first-page":"831","DOI":"10.15252\/emmm.201404396","volume":"7","author":"S Meidhof","year":"2015","unstructured":"Meidhof, S. et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol. Med. 7, 831\u2013847 (2015).","journal-title":"EMBO Mol. Med."},{"key":"1104_CR220","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrurol.2016.225","volume":"14","author":"V Rodriguez-Bravo","year":"2017","unstructured":"Rodriguez-Bravo, V. et al. The role of GATA2 in lethal prostate cancer aggressiveness. Nat. Rev. Urol. 14, 38\u201348 (2017).","journal-title":"Nat. Rev. Urol."},{"key":"1104_CR221","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/1878-0261.12164","volume":"12","author":"S K\u00fcffer","year":"2018","unstructured":"K\u00fcffer, S. et al. Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation. Mol. Oncol. 12, 256\u2013266 (2018).","journal-title":"Mol. Oncol."},{"key":"1104_CR222","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ccell.2014.11.013","volume":"27","author":"SJ Vidal","year":"2015","unstructured":"Vidal, S. J. et al. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 27, 223\u2013239 (2015).","journal-title":"Cancer Cell"},{"key":"1104_CR223","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-13-1869","volume":"20","author":"JS de Bono","year":"2014","unstructured":"de Bono, J. S. et al. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin. Cancer Res. 20, 1925\u20131934 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR224","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10637-018-0574-0","volume":"36","author":"P Barata","year":"2018","unstructured":"Barata, P. et al. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). Invest. New Drugs 36, 451\u2013457 (2018).","journal-title":"Invest. New Drugs"},{"key":"1104_CR225","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-20-0581","volume":"11","author":"S Sakuma","year":"2021","unstructured":"Sakuma, S. et al. Inhibition of nuclear pore complex formation selectively induces cancer cell death. Cancer Discov. 11, 176\u2013193 (2021).","journal-title":"Cancer Discov."},{"key":"1104_CR226","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cell.2018.07.015","volume":"174","author":"V Rodriguez-Bravo","year":"2018","unstructured":"Rodriguez-Bravo, V. et al. Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import. Cell 174, 1200\u20131215.e20 (2018).","journal-title":"Cell"},{"key":"1104_CR227","doi-asserted-by":"publisher","first-page":"380.e11","DOI":"10.1016\/j.urolonc.2022.05.019","volume":"40","author":"F Becker","year":"2022","unstructured":"Becker, F. et al. Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker. Urol. Oncol. 40, 380.e11\u2013380.e18 (2022).","journal-title":"Urol. Oncol."},{"key":"1104_CR228","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Mart\u00ednez-Reyes","year":"2021","unstructured":"Mart\u00ednez-Reyes, I. & Chandel, N. S. Cancer metabolism: looking forward. Nat. Rev. Cancer 21, 669\u2013680 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1104_CR229","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fonc.2018.00500","volume":"8","author":"EA Zaal","year":"2018","unstructured":"Zaal, E. A. & Berkers, C. R. The influence of metabolism on drug response in cancer. Front. Oncol. 8, 500 (2018).","journal-title":"Front. Oncol."},{"key":"1104_CR230","doi-asserted-by":"publisher","first-page":"61890","DOI":"10.18632\/oncotarget.11301","volume":"7","author":"L Ippolito","year":"2016","unstructured":"Ippolito, L. et al. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. Oncotarget 7, 61890\u201361904 (2016).","journal-title":"Oncotarget"},{"key":"1104_CR231","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/s41388-024-03059-4","volume":"43","author":"A-MK Beier","year":"2024","unstructured":"Beier, A.-M. K. et al. Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer. Oncogene 43, 2038\u20132050 (2024).","journal-title":"Oncogene"},{"key":"1104_CR232","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41388-018-0558-8","volume":"38","author":"F Su","year":"2019","unstructured":"Su, F., Ahn, S., Saha, A., DiGiovanni, J. & Kolonin, M. G. Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance. Oncogene 38, 1979\u20131988 (2019).","journal-title":"Oncogene"},{"key":"1104_CR233","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"1104_CR234","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41388-024-03057-6","volume":"43","author":"J Zhao","year":"2024","unstructured":"Zhao, J. et al. Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer. Oncogene 43, 2104\u20132114 (2024).","journal-title":"Oncogene"},{"key":"1104_CR235","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 22, 340\u2013355 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"1104_CR236","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41581-022-00601-z","volume":"18","author":"W Huang","year":"2022","unstructured":"Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L. & Lerman, L. O. Cellular senescence: the good, the bad and the unknown. Nat. Rev. Nephrol. 18, 611\u2013627 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1104_CR237","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1038\/onc.2015.331","volume":"35","author":"GM De Donatis","year":"2016","unstructured":"De Donatis, G. M. et al. NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. Oncogene 35, 2735\u20132745 (2016).","journal-title":"Oncogene"},{"key":"1104_CR238","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41388-024-03132-y","volume":"43","author":"J Yu","year":"2024","unstructured":"Yu, J. et al. Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-\u03baB activation and promotes docetaxel efficacy in prostate cancer. Oncogene 43, 2835\u20132849 (2024).","journal-title":"Oncogene"},{"key":"1104_CR239","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41585-023-00845-9","volume":"21","author":"M Carceles-Cordon","year":"2024","unstructured":"Carceles-Cordon, M., Orme, J. J., Domingo-Domenech, J. & Rodriguez-Bravo, V. The yin and yang of chromosomal instability in prostate cancer. Nat. Rev. Urol. 21, 357\u2013372 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"1104_CR240","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-6-79","volume":"6","author":"CD Scharer","year":"2008","unstructured":"Scharer, C. D. et al. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J. Transl. Med. 6, 79 (2008).","journal-title":"J. Transl. Med."},{"key":"1104_CR241","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05312-8","volume":"13","author":"S Sarwar","year":"2022","unstructured":"Sarwar, S., Morozov, V. M., Purayil, H., Daaka, Y. & Ishov, A. M. Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer. Cell Death Dis. 13, 868 (2022).","journal-title":"Cell Death Dis."},{"key":"1104_CR242","doi-asserted-by":"publisher","first-page":"107681","DOI":"10.1016\/j.isci.2023.107681","volume":"26","author":"MJ Martinez","year":"2023","unstructured":"Martinez, M. J., Lyles, R. D. Z., Peinetti, N., Grunfeld, A. M. & Burnstein, K. L. Inhibition of the serine\/threonine kinase BUB1 reverses taxane resistance in prostate cancer. iScience 26, 107681 (2023).","journal-title":"iScience"},{"key":"1104_CR243","doi-asserted-by":"publisher","first-page":"100937","DOI":"10.1016\/j.xcrm.2023.100937","volume":"4","author":"B Dhital","year":"2023","unstructured":"Dhital, B. et al. Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. Cell Rep. Med. 4, 100937 (2023).","journal-title":"Cell Rep. Med."},{"key":"1104_CR244","doi-asserted-by":"publisher","first-page":"71182","DOI":"10.18632\/oncotarget.11511","volume":"7","author":"CA Ocasio","year":"2016","unstructured":"Ocasio, C. A. et al. A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct. Oncotarget 7, 71182\u201371197 (2016).","journal-title":"Oncotarget"},{"key":"1104_CR245","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/cancers15112912","volume":"15","author":"C Sordo-Bahamonde","year":"2023","unstructured":"Sordo-Bahamonde, C. et al. Chemo-immunotherapy: a new trend in cancer treatment. Cancers 15, 2912 (2023).","journal-title":"Cancers"},{"key":"1104_CR246","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040\u20132051 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR247","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR248","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924\u2013937 (2019).","journal-title":"Lancet Oncol."},{"key":"1104_CR249","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"1104_CR250","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR251","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1104_CR252","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"1104_CR253","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","volume":"38","author":"Y Ma","year":"2013","unstructured":"Ma, Y. et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38, 729\u2013741 (2013).","journal-title":"Immunity"},{"key":"1104_CR254","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","volume":"74","author":"D Alizadeh","year":"2014","unstructured":"Alizadeh, D. et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 74, 104\u2013118 (2014).","journal-title":"Cancer Res."},{"key":"1104_CR255","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-14-0657","volume":"74","author":"J Kanterman","year":"2014","unstructured":"Kanterman, J. et al. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 74, 6022\u20136035 (2014).","journal-title":"Cancer Res."},{"key":"1104_CR256","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1202781","volume":"190","author":"A Sevko","year":"2013","unstructured":"Sevko, A. et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 190, 2464\u20132471 (2013).","journal-title":"J. Immunol."},{"key":"1104_CR257","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/cam4.2763","volume":"9","author":"M Yarchoan","year":"2020","unstructured":"Yarchoan, M. et al. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Med. 9, 1485\u20131494 (2020).","journal-title":"Cancer Med."},{"key":"1104_CR258","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nature03884","volume":"436","author":"S Gasser","year":"2005","unstructured":"Gasser, S., Orsulic, S., Brown, E. J. & Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186\u20131190 (2005).","journal-title":"Nature"},{"key":"1104_CR259","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1074378","volume":"5","author":"A Acebes-Huerta","year":"2016","unstructured":"Acebes-Huerta, A. et al. Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors. Oncoimmunology 5, e1074378 (2016).","journal-title":"Oncoimmunology"},{"key":"1104_CR260","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.7150\/thno.73152","volume":"12","author":"Z Ma","year":"2022","unstructured":"Ma, Z. et al. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics 12, 4965\u20134979 (2022).","journal-title":"Theranostics"},{"key":"1104_CR261","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","volume":"82","author":"EY Yu","year":"2022","unstructured":"Yu, E. Y. et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort b study. Eur. Urol. 82, 22\u201330 (2022).","journal-title":"Eur. Urol."},{"key":"1104_CR262","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak, D. P. et al. Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial. J. Clin. Oncol. 43, 1638\u20131649 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1104_CR263","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.trecan.2024.05.003","volume":"10","author":"R Pulido","year":"2024","unstructured":"Pulido, R., L\u00f3pez, J. I. & Nunes-Xavier, C. E. B7-H3: a robust target for immunotherapy in prostate cancer. Trends Cancer 10, 584\u2013587 (2024).","journal-title":"Trends Cancer"},{"key":"1104_CR264","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly, W. K. et al. Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study. Cancer Discov. 14, 76\u201389 (2024).","journal-title":"Cancer Discov."},{"key":"1104_CR265","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrclinonc.2013.30","volume":"10","author":"HI Scher","year":"2013","unstructured":"Scher, H. I., Morris, M. J., Larson, S. & Heller, G. Validation and clinical utility of prostate cancer biomarkers. Nat. Rev. Clin. Oncol. 10, 225\u2013234 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1104_CR266","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1101\/gad.305805.117","volume":"31","author":"DS Micalizzi","year":"2017","unstructured":"Micalizzi, D. S., Maheswaran, S. & Haber, D. A. A conduit to metastasis: circulating tumor cell biology. Genes. Dev. 31, 1827\u20131840 (2017).","journal-title":"Genes. Dev."},{"key":"1104_CR267","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nbt.2892","volume":"32","author":"JG Lohr","year":"2014","unstructured":"Lohr, J. G. et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat. Biotechnol. 32, 479\u2013484 (2014).","journal-title":"Nat. Biotechnol."},{"key":"1104_CR268","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","volume":"70","author":"D Lorente","year":"2016","unstructured":"Lorente, D. et al. Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer. Eur. Urol. 70, 985\u2013992 (2016).","journal-title":"Eur. Urol."},{"key":"1104_CR269","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","volume":"10","author":"HI Scher","year":"2009","unstructured":"Scher, H. I. et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 10, 233\u2013239 (2009).","journal-title":"Lancet Oncol."},{"key":"1104_CR270","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.eururo.2016.07.051","volume":"71","author":"NJ Vogelzang","year":"2017","unstructured":"Vogelzang, N. J. et al. Circulating tumor cells in a phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer. Eur. Urol. 71, 168\u2013171 (2017).","journal-title":"Eur. Urol."},{"key":"1104_CR271","doi-asserted-by":"publisher","first-page":"1060864","DOI":"10.3389\/fonc.2022.1060864","volume":"12","author":"CR Davies","year":"2022","unstructured":"Davies, C. R. et al. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer. Front. Oncol. 12, 1060864 (2022).","journal-title":"Front. Oncol."},{"key":"1104_CR272","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-05-0109","volume":"11","author":"HI Scher","year":"2005","unstructured":"Scher, H. I., Morris, M. J., Kelly, W. K., Schwartz, L. H. & Heller, G. Prostate cancer clinical trial end points: \u2018RECIST\u2019ing a step backwards. Clin. Cancer Res. 11, 5223\u20135232 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR273","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1158\/1078-0432.CCR-16-3081","volume":"23","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin. Cancer Res. 23, 5112\u20135122 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR274","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2017.6","volume":"19","author":"M Garg","year":"2017","unstructured":"Garg, M. Epithelial, mesenchymal and hybrid epithelial\/mesenchymal phenotypes and their clinical relevance in cancer metastasis. Expert. Rev. Mol. Med. 19, e3 (2017).","journal-title":"Expert. Rev. Mol. Med."},{"key":"1104_CR275","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/cancers11010059","volume":"11","author":"A Markiewicz","year":"2019","unstructured":"Markiewicz, A. et al. Spectrum of epithelial-mesenchymal transition phenotypes in circulating tumour cells from early breast cancer patients. Cancers 11, 59 (2019).","journal-title":"Cancers"},{"key":"1104_CR276","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/cells9020428","volume":"9","author":"J Dudas","year":"2020","unstructured":"Dudas, J., Ladanyi, A., Ingruber, J., Steinbichler, T. B. & Riechelmann, H. Epithelial to mesenchymal transition: a mechanism that fuels cancer radio\/chemoresistance. Cells 9, 428 (2020).","journal-title":"Cells"},{"key":"1104_CR277","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10585-021-10075-1","volume":"38","author":"T Pereira-Veiga","year":"2021","unstructured":"Pereira-Veiga, T. et al. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers. Clin. Exp. Metastasis 38, 239\u2013251 (2021).","journal-title":"Clin. Exp. Metastasis"},{"key":"1104_CR278","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138032","volume":"10","author":"L Xu","year":"2015","unstructured":"Xu, L. et al. Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS ONE 10, e0138032 (2015).","journal-title":"PLoS ONE"},{"key":"1104_CR279","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/JU.0000000000000475","volume":"203","author":"L Xu","year":"2020","unstructured":"Xu, L. et al. Noninvasive detection of clinically significant prostate cancer using circulating tumor cells. J. Urol. 203, 73\u201382 (2020).","journal-title":"J. Urol."},{"key":"1104_CR280","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","volume":"29","author":"SH Tolmeijer","year":"2023","unstructured":"Tolmeijer, S. H. et al. Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 29, 2835\u20132844 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1104_CR281","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.annonc.2021.03.196","volume":"32","author":"A Jayaram","year":"2021","unstructured":"Jayaram, A. et al. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Ann. Oncol. 32, 726\u2013735 (2021).","journal-title":"Ann. Oncol."},{"key":"1104_CR282","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca, N. M. et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat. Commun. 15, 1828 (2024).","journal-title":"Nat. Commun."},{"key":"1104_CR283","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/S1470-2045(22)00560-5","volume":"23","author":"AS Merseburger","year":"2022","unstructured":"Merseburger, A. S. et al. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Lancet Oncol. 23, 1398\u20131408 (2022).","journal-title":"Lancet Oncol."},{"key":"1104_CR284","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.euo.2024.08.006","volume":"8","author":"M Ruiz-Vico","year":"2025","unstructured":"Ruiz-Vico, M. et al. Liquid biopsy in progressing prostate cancer patients starting docetaxel with or without enzalutamide: a biomarker study of the PRESIDE phase 3b trial. Eur. Urol. Oncol. 8, 135\u2013144 (2025).","journal-title":"Eur. Urol. Oncol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01104-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01104-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01104-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:02:19Z","timestamp":1780920139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01104-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":284,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1038\/s41585-025-01104-9","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"3 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.P.P. reports personal fees from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Ipsen, Janssen, Merck & Company Inc., Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi-Aventis, Seattle Genetics and Urogen, and grants from Ada Cap (Advanced Accelerator Applications), Agensys Inc., Arvinas, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Company Limited, Eisai, Eli Lilly, Endocyte, Ferring, Genentech, Gilead Sciences, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi-Aventis and Seattle Genetics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}